NASDAQ:OPK

OPKO Health (OPK) Stock Forecast, Price & News

$1.45

+0.05 (+3.57%)

(As of 06/2/2023 ET)

Compare

Today's Range: $1.40
▼
$1.47
50-Day Range: $1.32
▼
$1.86
52-Week Range: $1.00
▼
$3.07

Volume: 3.10 million shs
Average Volume: 2.36 million shs
Market Capitalization: $1.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.13

OPKO Health MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 185.1% Upside
$4.13 Price Target
Short Interest: Bearish
9.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.65
Upright™ Environmental Score
News Sentiment: 0.35
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$1.78 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.28) to ($0.24) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

231st out of 983 stocks

Pharmaceutical Preparations Industry

104th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
OPKO Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.13, OPKO Health has a forecasted upside of 185.1% from its current price of $1.45.
Amount of Analyst Coverage
OPKO Health has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
9.82% of the float of OPKO Health has been sold short.
Short Interest Ratio / Days to Cover
OPKO Health has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.
Change versus previous month
Short interest in OPKO Health has recently increased by 1.87%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
OPKO Health does not currently pay a dividend.
Dividend Growth
OPKO Health does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
OPKO Health has received a 66.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Calcifediol", "Diagnostic test kits", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for OPKO Health is -1.65.

1.9

News and Social Media Coverage

News Sentiment
OPKO Health has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for OPKO Health this week, compared to 3 articles on an average week.
Search Interest
27 people have searched for OPK on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added OPKO Health to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OPKO Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,783,570.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
40.97% of the stock of OPKO Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 23.49% of the stock of OPKO Health is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for OPKO Health are expected to grow in the coming year, from ($0.28) to ($0.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OPKO Health is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OPKO Health is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OPKO Health has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About OPKO Health (NASDAQ:OPK) Stock

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

OPK Stock News Headlines

June 2, 2023 | finance.yahoo.com

Why Is OPKO Health (OPK) Down 17.2% Since Last Earnings Report?

June 1, 2023 | thestreet.com

'Mad Money' Lightning Round: Stick With Opko Health

June 4, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.

May 31, 2023 | americanbankingnews.com

OPKO Health (NASDAQ:OPK) Upgraded to "Hold" by StockNews.com

May 24, 2023 | benzinga.com

Carrier Screening Global Market Report 2023: Increase in Fetal Chromosomal Abnormalities Drives Growth

May 23, 2023 | msn.com

Factbox: Weight-loss drugs: the next gold rush

May 23, 2023 | markets.businessinsider.com

Nona Biosciences Enters into Antibody Discovery Agreement with OPKO Health's ModeX Therapeutics

May 12, 2023 | reuters.com

Factbox: Drugmakers bulk up with bets on weight-loss treatments

June 4, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

May 11, 2023 | msn.com

OPKO Health's Future After Merck Deal: Bright Or Uncertain

May 10, 2023 | finance.yahoo.com

Gary Nabel Spends US$541k On OPKO Health Stock \

May 10, 2023 | seekingalpha.com

OPKO Health: There Could Be A Chance For Upside

May 10, 2023 | americanbankingnews.com

Barrington Research Equities Analysts Decrease Earnings Estimates for OPKO Health, Inc. (NASDAQ:OPK)

May 9, 2023 | msn.com

OPKO Health And 2 Other Penny Stocks Insiders Are Aggressively Buying

May 9, 2023 | marketwatch.com

Monday 5/8 Insider Buying Report: OPK, ZION

May 9, 2023 | americanbankingnews.com

HC Wainwright Weighs in on OPKO Health, Inc.'s Q1 2024 Earnings (NASDAQ:OPK)

May 8, 2023 | americanbankingnews.com

OPKO Health, Inc. (NASDAQ:OPK) Insider Purchases $339,570.48 in Stock

May 7, 2023 | americanbankingnews.com

OPKO Health (NASDAQ:OPK) Price Target Cut to $5.40

May 7, 2023 | americanbankingnews.com

Research Analysts Offer Predictions for OPKO Health, Inc.'s Q1 2024 Earnings (NASDAQ:OPK)

May 6, 2023 | americanbankingnews.com

OPKO Health (NASDAQ:OPK) Shares Up 8.5% on Strong Earnings

May 5, 2023 | marketwatch.com

Rare Disease Genetic Testing Market Financial Overview Report 2023

May 5, 2023 | markets.businessinsider.com

Barrington Reaffirms Their Hold Rating on Opko Health (OPK)

May 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Opko Health (OPK) Buy Recommendation

May 4, 2023 | msn.com

OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates

May 4, 2023 | reuters.com

Novo Nordisk rivals see room to compete in $100 bln weight-loss drug market

May 4, 2023 | finance.yahoo.com

Q1 2023 OPKO Health Inc Earnings Call

May 3, 2023 | msn.com

Recap: OPKO Health Q1 Earnings

See More Headlines

OPK Price History

30 days | 90 days | 365 days | Advanced Chart

OPK Company Calendar

Last Earnings: 5/03/2023
Today: 6/04/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:OPK
CUSIP: 68375N10
CIK: 944809
Web: www.opko.com
Phone: (305) 575-4100
Fax: 305-575-6015
Employees: 4,196
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.13
High Stock Price Forecast: $5.40
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +185.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-328,400,000.00
Net Margins: -31.92%
Pretax Margin: -36.37%
Return on Equity: -13.63%
Return on Assets: -9.86%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 1.83
Quick Ratio: 1.49

Sales & Book Value

Annual Sales: $912.55 million
Price / Sales: 1.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.01 per share
Price / Book: 0.72

Miscellaneous

Outstanding Shares: 772,651,000
Free Float: 456,096,000
Market Cap: $1.12 billion
Optionable: Optionable
Beta: 1.66

Key Executives

Phillip Frost
Chairman & Chief Executive Officer

Elias A. Zerhouni
Vice Chairman & President

Adam E. Logal
CFO, Treasurer, Chief Accounting Officer & SVP

Jane H. Hsaio
Vice Chairman & Chief Technical Officer

Steven D. Rubin
Director & Executive Vice President-Administration

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OPK Stock - Frequently Asked Questions

Should I buy or sell OPKO Health stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPK shares.
View OPK analyst ratings or view top-rated stocks.
What is OPKO Health's stock price forecast for 2023?: 2 analysts have issued 1-year price objectives for OPKO Health's shares. Their OPK share price forecasts range from $3.00 to $5.40. On average, they predict the company's stock price to reach $4.13 in the next year. This suggests a possible upside of 185.1% from the stock's current price.
View analysts price targets for OPK or view top-rated stocks among Wall Street analysts.
How have OPK shares performed in 2023?: OPKO Health's stock was trading at $1.25 at the beginning of 2023. Since then, OPK shares have increased by 16.0% and is now trading at $1.45.
View the best growth stocks for 2023 here.
When is OPKO Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our OPK earnings forecast.
How were OPKO Health's earnings last quarter?: OPKO Health, Inc. (NASDAQ:OPK) issued its quarterly earnings data on Wednesday, May, 3rd. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The biotechnology company earned $237.60 million during the quarter, compared to analysts' expectations of $193.35 million. OPKO Health had a negative net margin of 31.92% and a negative trailing twelve-month return on equity of 13.63%. The company's revenue for the quarter was down 27.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.08) earnings per share.
What ETFs hold OPKO Health's stock?: ETFs with the largest weight of OPKO Health (NASDAQ:OPK) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Health Care Services ETF (XHS), VanEck Israel ETF (ISRA), iShares U.S. Healthcare Providers ETF (IHF), iShares Biotechnology ETF (IBB) and
What is Philip Frost's approval rating as OPKO Health's CEO?: 21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OPKO Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).
What is OPKO Health's stock symbol?: OPKO Health trades on the NASDAQ under the ticker symbol "OPK."
Who are OPKO Health's major shareholders?: OPKO Health's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (4.53%), State Street Corp (1.36%), Geode Capital Management LLC (1.09%), Dimensional Fund Advisors LP (0.89%), Charles Schwab Investment Management Inc. (0.63%) and Numerai GP LLC (0.29%). Insiders that own company stock include Elias A Zerhouni, Gary J Nabel, Jon R Cohen, Opko Health, Inc, Phillip Md Et Al Frost, Robert J Shovlin and Steven D Rubin.
View institutional ownership trends.
How do I buy shares of OPKO Health?: Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is OPKO Health's stock price today?: One share of OPK stock can currently be purchased for approximately $1.45.
How much money does OPKO Health make?: OPKO Health (NASDAQ:OPK) has a market capitalization of $1.12 billion and generates $912.55 million in revenue each year. The biotechnology company earns $-328,400,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.
How many employees does OPKO Health have?: The company employs 4,196 workers across the globe.
How can I contact OPKO Health?: OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The official website for the company is www.opko.com. The biotechnology company can be reached via phone at (305) 575-4100, via email at mmiller@lhai.com, or via fax at 305-575-6015.

This page (NASDAQ:OPK) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial